Trial Search Results
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection in HIV-infected MSM and HIV-infected women.
Stanford is currently not accepting patients for this trial.
National Institute of Allergy and Infectious Diseases (NIAID)
- Biological: Quadrivalent HPV Vaccine
- Biological: Placebo Vaccine for Male Participants Only
- Biological: Placebo Vaccine for Female Participants Only
- HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or
chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
confirmed by a licensed Western blot or a second antibody test by a method other than
the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
More information on this criterion can be found in the protocol.
- Laboratory values obtained within 45 days prior to entry by any U.S. laboratory that
has a Clinical Laboratory Improvement Amendment (CLIA) certification or its
equivalent, or at any network-approved non-U.S. laboratory that operates in accordance
with Good Clinical Practices and participates in appropriate external quality
1. Absolute neutrophil count (ANC) greater than 750 cells/mm^3
2. Hemoglobin greater than or equal to 9.0 g/dL
3. Platelet count greater than or equal to 75,000/mm^3
4. Serum creatinine less than or equal to three times the upper limit of normal
5. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])
and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT])
less than or equal to five times the ULN
6. Total or conjugated (direct) bilirubin less than or equal to 2.5 times the ULN
- For men, receptive anal sex (defined as receptive penile-anal sex or receptive
oral-anal sex with another man) within 1 year prior to entry
- Anal cytology result from specimen obtained within 45 days prior to entry
- HRA performed within 45 days prior to entry by a certified HRA provider with no
evidence of invasive or microinvasive anal cancer by anal biopsy or by visual
inspection if no biopsy was obtained. Note: refer to protocol for more information
about HRA certification process.
- For women, gynecologic examination (including screening for cervical disease by
exfoliative cytology with or without colposcopy) within 45 days prior to entry.
- For women of reproductive potential, a negative serum or urine pregnancy test within
45 days prior to study entry by any U.S. laboratory that has a CLIA certification or
its equivalent, or at any network-approved non-U.S. laboratory that operates in
accordance with Good Clinical Practices and participates in appropriate external
quality assurance programs. More information on this criterion can be found in the
- Confirmation of the availability of the anal swab, vaginal swab (women only) and Scope
oral rinse specimens for HPV DNA PCR obtained at screening. The site must confirm that
these samples have been entered into the Laboratory Data Management System (LDMS).
- Ability and willingness of participant or legal representative to provide informed
- History or current biopsy diagnosis of invasive or microinvasive cancer, i.e.:
- For all participants: anal or oropharyngeal cancer
- For men: penile cancer
- For women: cervical, vulvar, or vaginal cancer
- More information on this criterion can be found in the protocol.
- Anal, cervical, or vaginal cytological results suspicious for invasive carcinoma at
any point prior to entry
- Topical or surgical treatment for intra- or perianal intraepithelial neoplasia or
condyloma within 6 months prior to entry. More information on this criterion can be
found in the protocol.
- Prior receipt of one or more doses of an HPV vaccine
- Receipt of anticoagulants other than aspirin or nonsteroidal anti-inflammatory drugs
(NSAIDS) within 14 days prior to entry
- Known allergy/sensitivity or any hypersensitivity to yeast or any of the components of
the study product or its formulation. More information on this criterion can be found
in the protocol.
- Active drug or alcohol use or dependence or other condition that, in the opinion of
the site investigator, would interfere with adherence to study requirements
- Serious illness requiring systemic treatment and/or hospitalization within 21 days
prior to entry
- Hemophilia or other bleeding diatheses
- Use of any systemic antineoplastic or immunomodulatory treatment, systemic
corticosteroids other than inhaled corticosteroids or prednisone less than or equal to
10 mg (or equivalent), investigational vaccines, interleukins, interferons, growth
factors, or intravenous immunoglobulin (IVIG) within 45 days prior to study entry.
NOTE: Routine standard-of-care vaccines (including hepatitis A, hepatitis B,
influenza, pneumococcal, and tetanus vaccines) are not exclusionary.
- Expected treatment of hepatitis B or hepatitis C virus with immunomodulatory agents in
the 7 months after entry
Ages Eligible for Study
27 Years - N/A
Genders Eligible for Study